How Abbott Laboratories Makes its Money: Revenue Breakdown

How Does Abbott Laboratories Make its Money?

Abbott Laboratories (NYSE: ABT) is a diversified healthcare company operating across medical devices, diagnostics, nutritional products, and branded generic pharmaceuticals in approximately 160 countries. The company generated approximately $22.0 billion in total revenue for fiscal year 2024, up ~6% year-over-year on a reported basis (~8% organic, adjusting for foreign exchange headwinds), with net income of approximately $6.5 billion and a gross margin of approximately 55%.

Abbott’s defining characteristic is diversification — four distinct revenue segments with different growth rates, margins, and economic exposures. The Medical Devices segment (approximately 57% of revenue) is the growth engine, powered by FreeStyle Libre, the world’s leading continuous glucose monitor (CGM) for diabetes management, which generated approximately $6.3 billion in FY2024 revenue (+22% YoY) and is among the fastest-growing medical devices globally. The Diagnostics, Nutritional Products, and Established Pharmaceuticals segments provide revenue stability and emerging-market cash flow that buffers the cyclicality inherent in any single device franchise.

Abbott’s corporate structure today is the direct result of one of healthcare’s most significant strategic divestitures: the 2013 spinoff of AbbVie, which separated Abbott’s research-based pharmaceutical business (including Humira) into an independent company. Post-AbbVie, Abbott repositioned as a device-and-diagnostics-led company with a steady consumer nutrition business — a model designed for durable, recurring revenue rather than the binary risk/reward of drug patent cliffs. Understanding AbbVie vs. Abbott is essential context: Abbott is the instrument, diagnostics, and nutrition business; AbbVie is the pharmaceutical spinoff that has since grown into one of the world’s largest biopharmaceutical companies through Humira and Skyrizi.

Key Takeaways

• Abbott generated approximately $22.0B in FY2024 revenue (+~6% reported, ~8% organic) with ~$6.5B in net income and a ~55% gross margin across four segments: Medical Devices (~57%), Diagnostics (~16%), Nutritional Products (~17%), and Established Pharmaceuticals (~11%)
• FreeStyle Libre — Abbott’s CGM for diabetes — generated approximately $6.3B in FY2024 (+22% YoY), representing roughly half of the entire Medical Devices segment revenue; at an estimated 540 million diabetics globally plus 100M+ prediabetics, Libre remains early in its penetration of the addressable market
• The Medical Devices segment ($12–13B) is growing double-digits driven by Libre plus high-growth franchises in structural heart (MitraClip, Navitor TAVR), electrophysiology (Volt PFA catheter for cardiac ablation), and neuromodulation (spinal cord stimulation for chronic pain) — a diversified device portfolio that reduces single-product concentration risk despite Libre’s dominance
• Diagnostics (~$3.5B, ~16% of revenue) has normalised post-COVID — Abbott’s COVID rapid testing (BinaxNOW) drove multi-billion-dollar spikes in FY2021–2022; by FY2024 the base diagnostics business (Alinity lab analysers, core laboratory immunoassays, point-of-care testing) accounts for essentially all diagnostics revenue; this segment is now an organic mid-single-digit grower rather than a COVID-driven outlier
• Nutritional Products (~$3.7B, ~17%) — Ensure (adult nutrition, #1 globally), Similac (infant formula), PediaSure (paediatric), Pedialyte (electrolyte), Glucerna (diabetes nutrition) — provides stable, recession-resistant cash flow; the Similac infant formula recall (2022, Sturgis Michigan plant) created lasting share loss in the US infant formula market that is still being recovered
• Established Pharmaceuticals (~$2.4B, ~11%) — branded generic drugs sold in emerging markets (India, China, Brazil, Russia) — grows at 3–5% annually driven by rising healthcare access and spending in developing countries; provides geographic diversification into markets where Abbott has operated for decades
• The AbbVie spinoff context is critical: Abbott’s current 55% gross margin is deliberately lower than a pharma company’s gross margin — Abbott chose device/diagnostics economics (high-margin, device-plus-consumable recurring revenue) over pharma economics (higher peak margins, patent cliff risk); this is a structural portfolio philosophy, not a margin deficiency
• CGM competition is intensifying: Dexcom (DXCM) and the emerging GLP-1/CGM convergence (as Ozempic and Wegovy reduce diabetes prevalence while simultaneously increasing CGM demand for weight management monitoring) are the most important strategic variables for Abbott’s largest growth franchise

Abbott Laboratories (ABT) Business Model

Abbott’s business model is a diversified medical product company — it earns revenue by selling hardware devices, disposable consumables, diagnostic instruments and reagents, consumer nutritional products, and pharmaceutical formulations. Across all four segments, the recurring revenue dynamic is critical: devices require ongoing consumables (Libre sensors replaced every 14 days), diagnostic instruments require reagent refills, and nutritional products are repeat-purchase consumer goods. Abbott rarely earns revenue from a one-time sale.

Medical Devices: FreeStyle Libre and the CGM Ecosystem

FreeStyle Libre is Abbott’s most strategically important asset and the primary driver of Medical Devices segment revenue growth. The device mechanics and business model:

How FreeStyle Libre works:

• A small sensor (coin-sized, applied to the back of the upper arm) continuously measures interstitial fluid glucose levels every minute
• Data is read by waving a reader device or NFC-enabled smartphone over the sensor
• Libre 2 (current generation in most markets): sensor worn for 14 days, then replaced
• Libre 3 (latest generation): smaller sensor, real-time Bluetooth streaming to smartphones, optional alarms for high/low glucose events
• No finger-prick blood glucose test required — this convenience advantage over traditional glucometers is the core consumer value proposition

The CGM razor-and-blades business model:

• The initial sensor applicator (reader or first-sensor kit) is sold at a modest price (~$70 retail for the reader; often subsidised or free through pharmacy/insurance programmes)
• The recurring consumable — replacement sensors — is the business: sensors are replaced every 14 days, generating a recurring per-patient revenue stream of approximately $30–50/month (retail) or equivalent through insurance reimbursement
• At ~$6.3B in FY2024 revenue across millions of installed patients, Libre generates highly predictable recurring revenue regardless of new patient acquisitions in any given quarter
• Insurance reimbursement coverage (Medicare, Medicaid, private insurance in the US; NHS in the UK; statutory health insurance in Germany and France) dramatically expands addressable market — patients who receive CGM sensors as a covered prescription benefit show significantly higher adherence and longer sensor wear duration than self-pay patients

The addressable market:

• Type 1 diabetes globally: ~8–9 million people (essentially all require insulin management; CGM is the standard of care)
• Type 2 diabetes on insulin: ~100+ million people — a massive under-penetrated segment where CGM adoption has historically been low but is accelerating with Libre 2/3 approval for Type 2 insulin users
• Type 2 non-insulin and prediabetes: hundreds of millions of people — emerging market as CGMs gain approval and reimbursement for metabolic monitoring and weight management (converging with the GLP-1 drug revolution)
• The GLP-1 dynamic: Ozempic/Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide) reduce HbA1c and weight in Type 2 diabetics — some investors worry this reduces CGM demand; Abbott’s view is that GLP-1 users still benefit from CGM to monitor their metabolic response, and the obesity treatment market may actually expand total CGM users

Other Medical Devices franchises:

Structural Heart: MitraClip (a catheter-based device to repair leaky mitral heart valves without open-heart surgery) and the Navitor TAVR system (transcatheter aortic valve replacement). These procedures address the millions of heart failure patients with valvular heart disease who are too high-risk for conventional surgery. Structural heart is a high-growth, high-ASP device category ($15,000–30,000+ per procedure) with expanding clinical evidence and physician adoption.

Electrophysiology: Mapping and ablation systems for treating abnormal heart rhythms (arrhythmias). Abbott’s Volt pulsed-field ablation (PFA) catheter targets atrial fibrillation (AFib) — the most common cardiac arrhythmia. PFA is a newer ablation technology using electrical pulses rather than heat or cold to create precise lesions; it has faster procedure times and a better safety profile than traditional radiofrequency ablation. Abbott, Medtronic, Boston Scientific, and Johnson & Johnson all compete in the EP ablation market, with PFA being the key technology battleground.

Neuromodulation: Spinal cord stimulators (Proclaim™ platform) and deep brain stimulation (DBS) systems. Spinal cord stimulation treats chronic pain that has not responded to other therapies; DBS treats Parkinson’s disease and essential tremor. Both are implanted devices with ongoing clinic-based programming and electrode/battery replacement revenue.

Vascular: Drug-eluting stents, peripheral vascular catheters, and haemostasis products — a more mature segment growing at low-to-mid single digits.

Diagnostics: From COVID Supercycle to Core Laboratory Base

Abbott’s Diagnostics segment is the clearest example of how COVID distorted and then normalised Abbott’s financials:

FY2022 COVID peak: Abbott’s BinaxNOW rapid COVID-19 antigen test drove billions in diagnostics revenue — US government orders, pharmacy shelf sales, and international distribution made Abbott one of the primary winners of the COVID rapid testing boom. Diagnostics revenue exceeded $9–10B in FY2022 at peak.

FY2024 post-COVID normalisation: COVID testing revenue declined to negligible levels by FY2024, bringing Diagnostics to approximately $3.5B — the core base business that existed before the pandemic.

The base diagnostics business consists of:

• Core Laboratory (Alinity analyser family): Automated blood testing platforms installed in hospital and commercial labs. Revenue model: instrument placement (often subsidised or leased) with recurring reagent and supply revenue per test run. Alinity competes with Roche, Siemens Healthineers, and Becton Dickinson in the core lab space. Each installed Alinity system generates multi-year reagent revenue through long-term reagent supply agreements
• Rapid Diagnostics / Point-of-Care: Handheld and benchtop testing devices for infectious disease, cardiac markers, and metabolic panels. BinaxNOW (reformulated for influenza and RSV post-COVID) and the i-STAT system (blood gas, electrolyte, and troponin testing at the point of care) are key platforms
• Molecular Diagnostics: PCR and molecular testing platforms for infectious disease and oncology marker detection

Nutritional Products: Durable Consumer Cash Flow

Abbott’s Nutritional Products segment sells medical and consumer nutrition products globally. The segment is divided into:

Paediatric nutrition: Similac (infant formula — US/international), PediaSure (nutritional supplement for children 2–13), and Pedialyte (oral electrolyte solution for dehydration from illness). The Sturgis, Michigan manufacturing plant recall in February 2022 — linked to Cronobacter bacteria in infant formula — was one of the most significant events in Abbott’s recent history. The plant closure and resulting US infant formula shortage forced Abbott to rebuild its Similac market share from near-zero to a still-recovering position by FY2024. Brand trust with paediatric healthcare providers, previously built over decades, was partially eroded and is still being rebuilt.

Adult nutrition: Ensure (the #1 adult nutritional drink globally), Glucerna (specialised nutrition for people with diabetes), and Juven (for wound healing and surgical recovery). Ensure is a branded repeat-purchase consumer good sold in pharmacies, supermarkets, and healthcare settings — a stable, GDP-correlated revenue stream that grows with ageing population demographics globally.

Established Pharmaceuticals: Emerging Market Infrastructure

The Established Pharmaceuticals segment sells branded generic pharmaceutical products in approximately 150 emerging markets — primarily India, China, Brazil, Russia, and other developing economies. These are off-patent pharmaceutical compounds that Abbott formulates, brands, and distributes under trusted local brand names (leveraging Abbott’s decades-long relationships with healthcare providers in these markets).

Revenue grows at 3–5% annually, driven by rising healthcare access, growing middle-class populations, and increasing pharmaceutical spending in developing countries. The segment provides geographic and sector diversification — its growth drivers are different from the device/diagnostics cycles that affect the rest of Abbott’s business.

Abbott Laboratories Competitors

Medtronic — the most direct medical device competitor across multiple segments

Medtronic is Abbott’s closest structural competitor, with overlapping franchises across CGM (Medtronic Guardian glucose monitoring system), cardiac rhythm management (pacemakers, defibrillators, and EP mapping/ablation — including PFA with the PulseSelect system), neuromodulation (spinal cord stimulators and DBS), and structural heart. In CGM, Medtronic’s Guardian 4 system competes directly with FreeStyle Libre, though Abbott holds a commanding market share advantage driven by Libre’s lower price, pharmacy availability, and consumer-friendly sensor form factor. The Abbott-Medtronic competition in pulsed-field ablation (Abbott’s Volt vs. Medtronic’s PulseSelect) is the current battleground in electrophysiology — a multi-billion-dollar market where first-mover advantage with compelling clinical data is the key competitive variable.

Johnson & Johnson — broad medtech and diagnostics competitor

Johnson & Johnson’s MedTech segment (post-Kenvue consumer spinoff) competes with Abbott across electrophysiology (J&J’s Biosense Webster mapping and ablation franchise is the EP market leader globally), orthopaedics (no direct Abbott overlap), and surgical robotics. In EP, Biosense Webster’s CARTO 3 mapping system and ThermoCool ablation catheter portfolio is the incumbent market leader that Abbott’s PFA technology is attempting to disrupt. J&J does not compete in CGM.

Becton Dickinson — diagnostics and life sciences competitor

Becton Dickinson (BD) competes with Abbott primarily in the diagnostics space — BD’s diagnostic systems (BD MAX molecular platform, BD Veritor rapid antigen tests) overlap with Abbott’s laboratory and rapid diagnostics franchise. BD also competes in medication delivery devices that occasionally overlap with Abbott’s vascular portfolio. The core lab competition (BD vs. Abbott vs. Roche vs. Siemens) is primarily a reagent-volume economics competition — hospitals sign multi-year reagent supply contracts and switching costs are high, making installed base loyalty the dominant competitive dynamic.

Dexcom — the primary CGM competitor (not publicly listed on Visuwire)

Dexcom is Abbott’s most important competitive threat for the FreeStyle Libre franchise. Dexcom’s G7 CGM competes directly with Libre 3 in the US and European markets. The key product differentiation: Dexcom G7 is FDA-cleared for integration with automated insulin delivery (AID) systems (like Omnipod and Tandem t:slim pump), making it the preferred CGM for Type 1 diabetics on hybrid closed-loop therapy — a smaller but more insulin-intensive user segment. Abbott’s Libre 3 has been pursuing AID integrations and expanding its clinical indications. Abbott’s competitive advantages: lower sensor price, pharmacy OTC availability (Libre 2 approved for over-the-counter sale in the US — the first CGM to achieve this), larger global installed base, and broader reimbursement coverage in key European markets.

Nestlé Health Science and Danone — nutritional products competition

In nutritional products, Abbott competes with Nestlé Health Science (Boost, Resource) and Danone (Nutricia) for adult and paediatric medical nutrition market share globally. This is a branded consumer goods competition rather than a medtech device competition — relationships with hospital dietitians, pharmacists, and paediatric healthcare providers drive formulary positioning.

Revenue Breakdown

Note: Segment figures are approximate based on publicly disclosed proportions and reported growth rates. Financial data sourced from Abbott SEC Filings.

Medical Devices growing ~14% while total revenue grows ~7% demonstrates the segment mix shift underway: Medical Devices is becoming a larger share of Abbott’s total revenue as Libre scales. Diagnostics declining ~5% reflects continued COVID testing normalisation — the base diagnostics business (Alinity, i-STAT) grew modestly, but the prior-year comparison still included some residual COVID test revenue. Nutrition and Pharma segments are GDP-correlated growers, providing stability without driving material incremental revenue.

Revenue Trend (3-Year)

FY2022 was a distorted peak (massive COVID testing revenue in Diagnostics); FY2023 the trough as COVID testing collapsed; FY2024 the resumption of organic growth driven by Medical Devices. The underlying business trend — excluding COVID diagnostics — has been consistently growing: Medical Devices has grown double digits annually, and the ex-COVID base is expanding. Gross margin expansion (52% → 55%) reflects the increasing mix of high-margin Medical Devices revenue (particularly Libre sensor consumables) relative to the lower-margin nutrition and pharma segments.

Abbott Laboratories (ABT) Income Statement

Financial data sourced from Abbott SEC Filings. Figures are approximate.

Abbott’s net income ($6.5B) exceeding operating income ($4.3B) reflects non-operating items — principally investment income on Abbott’s substantial cash holdings and the benefit of lower effective tax rates through international structures. Free cash flow of ~$5.5B confirms that Abbott’s earnings are cash-generative and support both the dividend (Abbott is a Dividend Aristocrat with 50+ consecutive years of dividend increases) and continued M&A capacity.

Abbott Laboratories (ABT) Key Financial Metrics

• Gross Margin: ~55% — Abbott’s gross margin reflects the blended mix of high-margin Medical Devices (Libre sensors carry gross margins estimated at 65–70%+) and lower-margin Nutritional Products (estimated 35–40%) and Pharmaceuticals (estimated 50–55%). As Medical Devices grows as a share of total revenue, blended gross margin should expand toward 57–60% over time, assuming Libre’s recurring consumable margins are sustained

• Operating Margin: ~20% — Solid for a diversified healthcare company. The operating margin reflects Abbott’s significant R&D spend (~$2.9B, ~13% of revenue) required to sustain device and diagnostics innovation, and the sales force investments required to maintain relationships with hospitals, physicians, and healthcare systems globally. Mature medtech peers like Medtronic operate at similar margins; pure-play high-growth device companies often operate at lower margins during growth phases

• FreeStyle Libre Revenue: ~$6.3B (+22% YoY) — The most watched metric for Abbott investors. Libre’s growth rate is the single most important variable for Abbott’s stock performance. A deceleration below 15% growth would raise questions about market saturation; continued 20%+ growth requires sustained Type 2 and non-insulin penetration expansion

• Return on Invested Capital: Abbott generates free cash flow of ~$5.5B annually on an enterprise value of ~$200B, implying a ~2.75% FCF yield — below the S&P 500 average, which reflects the premium growth multiple assigned to FreeStyle Libre’s growth trajectory. ROIC on invested capital is strong, reflecting the high returns on Libre’s consumable-based model once the initial sensor platform development costs are sunk

• Dividend Aristocrat: Abbott has increased its dividend for 50+ consecutive years — one of only ~65 S&P 500 companies to achieve this. The dividend yield (~2%) and consistent payout growth makes Abbott a core holding for healthcare-focused dividend investors

• R&D Spend: ~$2.9B (~13% of revenue) — Sustained R&D investment funds next-generation Libre sensors (Libre 3+, Lingo for wellness), next-generation PFA catheters, and diagnostic platform upgrades. Abbott’s R&D intensity is below pharma peers (which typically spend 15–25% of revenue on R&D) but above industrial companies, appropriate for a device/diagnostics company where innovation cycles are 3–7 years rather than 10–15 years

Is Abbott Laboratories Profitable?

Yes — Abbott is firmly and consistently profitable. The company reported approximately $6.5 billion in net income in FY2024, representing a net margin of approximately 30%. Operating income was approximately $4.3 billion (20% operating margin). Abbott has been continuously profitable for decades and is one of the few large-cap healthcare companies to have increased its dividend annually for 50+ consecutive years — a feat that requires consistent, predictable profitability regardless of economic cycle.

Abbott’s profitability is structurally supported by the recurring consumable revenue model: once a patient is on FreeStyle Libre, they require replacement sensors every 14 days for as long as they manage diabetes — a multi-year or life-long recurring revenue relationship. This visibility into future revenue streams (combined with long-term reagent supply contracts in Diagnostics) provides financial durability that justifies Abbott’s sustained profitability through diverse economic environments.

Abbott Laboratories (ABT): What to Watch

1. FreeStyle Libre growth rate — The single most important metric for Abbott investors. Libre growing 22% in FY2024 is exceptional for a product at $6.3B in revenue. Watch the quarterly growth rate and specifically: Type 2 non-insulin penetration (management guidance on Libre prescriptions for non-insulin Type 2 patients), OTC sales volume (Libre 2 OTC availability in the US opens a self-pay consumer market), and any reimbursement expansions in major markets. A deceleration below 15% growth would be the first signal that the Libre growth phase is maturing

2. CGM competitive landscape and Dexcom dynamics — Abbott and Dexcom are the two dominant CGM companies; their relative market share shifts are watched closely. Dexcom G7’s integration with automated insulin delivery systems (a clinical advantage for Type 1 users) is the primary threat to Libre’s market share in the most intensive diabetes management segment. Watch for any Abbott Libre 3+ announcements regarding AID system integrations, which would close this product gap. Also watch the GLP-1 drug adoption impact: as semaglutide and tirzepatide become more prevalent for Type 2 diabetes and obesity management, does CGM adoption increase (monitoring metabolic response to GLP-1) or decrease (better-controlled blood sugar reduces monitoring urgency)?

3. Pulsed-field ablation market share in electrophysiology — The Volt PFA catheter (Abbott) vs. PulseSelect (Medtronic) vs. Farapulse (Boston Scientific, already approved and in market) race is one of the most competitive device category battles. PFA is a technology shift in AFib ablation — faster, safer, and more precise than radiofrequency ablation. The company that achieves dominant PFA market share captures a multi-billion-dollar recurring catheter replacement business. Watch clinical data presentations (major cardiology conferences: ACC, ESC, HRS) and hospital adoption rates for each company’s PFA system

4. Similac infant formula market share recovery — The 2022 Sturgis plant recall caused Similac’s US market share to collapse (from ~40% pre-recall to below 20% during the shortage). Abbott has been investing heavily in Similac brand rebuilding — manufacturing investment, physician outreach, and retailer promotion. Watch quarterly US infant formula market share data (Nielsen retail scanner data) for evidence of sustained Similac share recovery. The brand trust rebuild is a multi-year process that requires consistent product safety and clinical advocacy

5. Diagnostics base business organic growth — Post-COVID normalisation is essentially complete. The core Alinity lab diagnostics business should return to mid-single-digit organic growth driven by instrument placements and reagent volume growth. Watch management guidance on Diagnostics segment organic growth — any acceleration above mid-single digits (driven by Alinity placements, molecular diagnostic expansion, or new rapid test launches for infectious disease beyond COVID) would be a positive segment re-rating catalyst

6. Emerging market Established Pharmaceuticals exposure — The segment’s revenue includes operations in Russia, which carries geopolitical risk (Western sanctions, potential asset confiscation, currency restrictions). Watch for any management commentary on Russia operations specifically, and whether Abbott is taking steps to reduce or monetise its Russia exposure. India and China exposure (significant) carries different risks: regulatory pricing interventions in China and competitive pressure from domestic generic manufacturers in both markets

7. M&A and capital allocation — Abbott generates ~$5.5B in annual free cash flow with a relatively modest dividend payout (~$2.5B annually). The remaining ~$3B in annual excess free cash flow funds share buybacks and potential acquisitions. Abbott has historically been an active acquirer (St. Jude Medical in 2017 for $30B built the EP and neuromodulation franchises). Any large acquisition announcement should be evaluated for strategic fit with the Medical Devices growth platform and balance sheet impact — Abbott’s current leverage is manageable, but a large debt-funded deal would change the financial profile meaningfully

Abbott Laboratories (ABT) Financial Summary

Abbott Laboratories (ABT) generated approximately $22.0 billion in total revenue in fiscal year 2024 (~+7% YoY reported, ~+8% organic) with approximately $6.5 billion in net income and a ~55% gross margin — the result of a deliberate portfolio strategy built on recurring-revenue medical devices, diagnostic instruments and reagents, consumer nutritional products, and emerging-market pharmaceuticals. FreeStyle Libre at ~$6.3B (+22%) is the growth engine, the most valuable individual product franchise in Abbott’s portfolio, and the primary reason Abbott trades at a healthcare sector premium. The post-AbbVie Abbott is a structurally different company from its pre-2013 self — more device-driven, less pharmaceutical-dependent, and designed for durable recurring revenue over patent-cliff-exposed blockbuster drugs. For the closest competitive benchmark across CGM, structural heart, and electrophysiology, see How Medtronic Makes its Money. For the diagnostics segment competitive comparison, see How Becton Dickinson Makes its Money.